xiaflex
xiaflex: sourced relationships with 3 companies · 6 clinical trials tracked.
xiaflex evidence translation
What we can confirm
6 tracked trials
What it means
What to watch
Prepared research question
What is verified about xiaflex, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (3)
| Company | Dated record stage |
|---|---|
| BIOSPECIFICS TECHNOLOGIES CORP (BSTC) Uterine fibroids | Phase 1 |
| Endo International plc (ENDP) | Preclinical |
| Endo LP (NDOI) arthrofibrosis of the knee post arthroplasty | Phase 2 |
Clinical Trial Registry Records (6)
Efficacy of a Step-wise Protocol in Optimizing CCH Outcomes in Men With Peyronie's Disease
Primary endpoint: Penile Curvature
A Phase 2, Double-blind, Randomized, Placebo-controlled, Dose-ranging Study to Assess the Efficacy, Safety, and Tolerability of EN3835 vs Placebo in the Treatment of Plantar Fasciitis (PFA)
Primary endpoint: Change from Baseline at Week 12 in the Weekly Mean of the Average Daily (24-hour) Pain (ADP) Score as Measured on the Pain Intensity Numeric Rating Scale (NRS)
A Phase 3, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis (PFI) (Also Known as Ledderhose Disease)
Primary endpoint: Change from Baseline to Week 12 in the Weekly Mean of the Average Daily (24-hour) Pain (ADP) Score as Measured on the Pain Intensity Numeric Rating Scale (NRS)
Safety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional Platelet Rich Plasma for Peyronie's Disease
Primary endpoint: Number of Treatment Related Adverse Events
Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis
Primary endpoint: Change From Baseline to Day 57 in the Foot Function Index (FFI) Pain Subscale Score
To Assess the Effectiveness of Multiple Dose, Multiple Concentrations of Clostridium Histolyticum-aases, Qwo, for the Treatment of Mild to Moderate Cellulite in Adult Females to the Buttocks and Thighs
Primary endpoint: Proportion of Subjects With ≥1-point Improvement on Investigator Global Aesthetic Improvement Scale (I-GAIS) at Day 90 (Buttocks)
Frequently asked questions
Which companies have sourced relationships with xiaflex?
xiaflex has dated SEC/FDA relationship records for BIOSPECIFICS TECHNOLOGIES CORP, Endo International plc, Endo LP.
How many clinical trials involve xiaflex?
BioSniper tracks 6 clinical trials involving xiaflex.